Mavyret Shortage Update: What Patients Need to Know in 2026

If you've searched online for information about a "Mavyret shortage," you're not alone. Many patients prescribed this hepatitis C medication have trouble filling it—leading to the reasonable assumption that there must be a national shortage. Here's the current picture in 2026.

Is Mavyret in a Shortage as of 2026?

No. Mavyret is not listed on the FDA's official drug shortage database as of 2026. AbbVie, the manufacturer, continues to produce and distribute the drug without reported supply disruptions. The FDA shortage list is updated regularly and currently does not include Mavyret or its components, glecaprevir and pibrentasvir.

That said, many patients experience real access challenges—and these struggles are genuine even if they don't constitute a formal shortage. Understanding the difference matters for how you respond.

Why Are Patients Having Trouble Getting Mavyret?

The difficulty filling Mavyret isn't about manufacturing supply—it's about the drug's specialty status and the insurance system. Here's a breakdown of the real barriers:

Prior authorization: Most insurance plans require documented clinical justification before covering Mavyret. This process can take days to weeks.

Specialty pharmacy routing: Many plans require Mavyret to be filled at a designated specialty pharmacy rather than a retail drugstore.

Low stocking: Many retail pharmacies don't keep Mavyret on hand because it's expensive and infrequently prescribed at the local level.

Cost barriers: With a cash price exceeding $14,000 for an 8-week course, patients without insurance or savings programs can't afford to fill it.

What Is the Current Availability of Mavyret in 2026?

Mavyret remains commercially available through specialty pharmacies and select retail pharmacies in 2026. The expanded indication approved by the FDA in June 2025—making Mavyret the first approved treatment for acute HCV—has likely increased awareness and prescriptions, which may put additional demand on pharmacy inventory in some areas.

For patients in rural areas or those whose insurance doesn't have a broad specialty pharmacy network, access is harder. But the drug itself is available—the challenge is navigating the system to get it.

What to Do If You Can't Get Mavyret Right Now

Contact AbbVie patient support at 1-877-628-9738. They can help identify in-network specialty pharmacies, check on PA status, and connect you with financial assistance.

Apply for myAbbVie Assist if you're uninsured or underinsured. Eligible patients can receive Mavyret at no cost through this program.

Ask your doctor about alternatives. If access barriers to Mavyret are persistent, Epclusa (with a generic now available) or Harvoni may be more accessible options, depending on your HCV genotype and clinical situation.

Use a service like medfinder to identify which pharmacies near you currently have Mavyret in stock and can fill your prescription.

How Urgent Is It to Start Mavyret Treatment?

Hepatitis C is a curable disease, and the sooner treatment begins, the better. In patients with acute HCV (infection within the past 6 months), starting treatment immediately limits the chance of developing chronic infection. For chronic HCV, waiting weeks or even months is generally not catastrophic—but every delay allows some ongoing liver damage to continue.

The bottom line: don't let access barriers become an indefinite delay. Hepatitis C is now highly curable with modern treatments—act urgently to resolve whatever barrier is in your way.

How to Stay Updated on Mavyret Availability

Check the FDA drug shortage database at fda.gov/drugs/drug-shortages for official updates. For real-time pharmacy availability near you, medfinder contacts local pharmacies on your behalf to confirm who can fill your prescription. You can also read our guide: how to find Mavyret in stock near you.